You have free access to this content

In vivo induced antigen technology (IVIAT)

  1. Sean M. Rollins1,
  2. Amanda Peppercorn1,
  3. Long Hang1,
  4. Jeffrey D. Hillman2,3,
  5. Stephen B. Calderwood1,4,
  6. Martin Handfield2,
  7. Edward T. Ryan1,5,6

Article first published online: 21 DEC 2004

DOI: 10.1111/j.1462-5822.2004.00477.x

Issue

Cellular Microbiology

Cellular Microbiology

Volume 7, Issue 1, pages 1–9, January 2005

Additional Information

How to Cite

Rollins, S. M., Peppercorn, A., Hang, L., Hillman, J. D., Calderwood, S. B., Handfield, M. and Ryan, E. T. (2005), In vivo induced antigen technology (IVIAT). Cellular Microbiology, 7: 1–9. doi: 10.1111/j.1462-5822.2004.00477.x

Author Information

  1. 1

    Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.

  2. 2

    Center for Molecular Microbiology, Department of Oral Biology, University of Florida, Gainesville, FL, USA.

  3. 3

    Oragenics, 12085 Research Drive, Alachua, FL, USA.

  4. 4

    Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, MA, USA.

  5. 5

    Department of Medicine, Harvard Medical School, Boston, MA, USA.

  6. 6

    Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA, USA.

* E-mail etryan@partners.org; Tel. (+1) 617 7266175; Fax (+1) 617 7267416.

Publication History

  1. Issue published online: 21 DEC 2004
  2. Article first published online: 21 DEC 2004
  3. Received 23 July, 2004; revised 30 August, 2004; accepted 2 September, 2004.

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (182K)

Summary

In vivo induced antigen technology (IVIAT) is a technique that identifies pathogen antigens that are immunogenic and expressed in vivo during human infection. IVIAT is complementary to other techniques that identify genes and their products expressed in vivo. Genes and gene pathways identified by IVIAT may play a role in virulence or pathogenesis during human infection, and may be appropriate for inclusion in therapeutic, vaccine or diagnostic applications.

View Full Article (HTML) Get PDF (182K)